Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.44 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17920476 | 0.86 | RNASE1 (0.45) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL28675451 | 0.81 | TK1 (0.43) | TK1LMNATSHRALBPKM | |
| 3-Methylthymidine SCHEMBL17794002 | 0.81 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 | |
| 3-Methylthymidine SCHEMBL2246880 | 0.81 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 | |
| 3-Methylthymidine SCHEMBL28122219 | 0.81 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 | |
| 3-Methylthymidine SCHEMBL6062749 | 0.81 | TK1 (0.50) | TK1LMNATSHRBLMPMP22 | |
| SCHEMBL31685660 | 0.81 | POLB (0.41) | TK1RNASE1P2RY1 | |
| SCHEMBL20369177 | 0.80 | TK1 (0.42) | TK1LMNATSHRALBPKM | |
| SCHEMBL17471534 | 0.80 | TK1 (0.42) | TK1LMNATSHRALBPKM | |
| SCHEMBL8428685 | 0.80 | TK1 (0.67) | TK1RNASE1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | TK1 950/4885RNASE1 3/4885LMNA 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.